Ensituximab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | MUC5AC |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6342H9800N1678O1985S46 |
| Molar mass | 142.8 kg/mol g·mol−1 |
  (what is this?) (verify) | |
Ensituximab (NPC-1C) is a chimeric monoclonal antibody under development for as a candidate for treatment of cancers.[1] The target of the antibody is uncertain and is described as "human colorectal and pancreatic carcinoma-associated antigens", a set of tumor antigens isolated from human cancers.[2] The target might be Mucin 5AC.[3]
The antibody was discovered by scientists at Neogenix Oncology using tumor antigens that had been identified years earlier by Ariel Hollinshead; the founder of Neogenix had founded a prior company based on Hollinshead's work as well.[4] Neogenix worked with Selexis to develop the CHO cell line expressing ensituximab[5][6] and also worked with Goodwin Biotechnology Inc on process development.[7]
Ensituximab was granted orphan drug designation for pancreatic cancer by the FDA in 2010.[8] Results from a small Phase II trial in people with pancreatic or colon cancer presented in 2012 were not promising with regard to efficacy in treating pancreatic cancer.[3]
In 2011 Neogenix was forced to declare bankruptcy because the SEC opened an investigation into its use of unregistered broker-dealers in the course of raising $30M, and it could not raise further funds; in 2012 Neogenix sold its assets to a group of its investors who had formed a company called Precision Biologics.[9]
In 2016, Precision released data from a Phase II trial colorectal cancer and at that time was working with Cytovance Biologics as its contract manufacturing organization.[10]
References
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ensituximab" (PDF). American Medical Association.
- ^ "Ensituximab". NCI Drug Dictionary. Retrieved 31 January 2017.
- ^ a b Strimpakos, Alexios S.; Syrigos, Kostas N.; Saif, Muhammad Wasif (10 March 2012). "Novel Agents in Early Phase Clinical Studies on Refractory Pancreatic Cancer". Journal of the Pancreas. 13 (2): 166–168. ISSN 1590-8577. PMID 22406592.
- ^ Morrison, Trista (July 11, 2007). "Neogenix Uses Cancer Vaccine And Antibody Approaches". BioWorld Today.
- ^ Neogenix Oncology, Inc. - Pharmaceuticals & healthcare - Deals and alliances profile. (2015). London: Global Data Ltd.
- ^ "Press ReleaseL Selexis and Neogenix Oncology Execute Commercial License Agreement - Selexis SA". Selexis SA. 5 January 2011.
- ^ "From Vaccines To Monoclonal Antibodies: Creating Milestones In Cancer Theranostics". Frost & Sullivan. 14 September 2007.
- ^ Staff (1 December 2010). "FDA Pipeline Preview, December 2010 (Ezogabine, Solesta, Dutasteride, Finasteride, Octaplex, SF1126, MP4CO, Ensituximab, Naloxone, CBLB502)". Formulary Journal.
- ^ Davie, Alexander J. (5 October 2012). "Neogenix Oncology: A Good Case Study on Securities Law (Non)Compliance by a High Growth Company – Part 1: How It All Happened". Strictly Business.. "Neogenix Oncology: A Good Case Study on Securities Law (Non)Compliance by a High Growth Company – Part 2: What Neogenix Did". Strictly Business. 24 October 2012.. "Neogenix Oncology: A Good Case Study on Securities Law (Non)Compliance by a High Growth Company – Part 3: When the Genie Can't Be Put Back in the Bottle". Strictly Business. 17 November 2012.
- ^ "Ensituximab". AdisInsight. Retrieved 30 January 2017.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |